Sign Up to like & get
recommendations!
0
Published in 2018 at "Indian Journal of Psychological Medicine"
DOI: 10.4103/ijpsym.ijpsym_374_17
Abstract: The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application Lurasidone (Latuda, Sunovion Pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13–17 years of age. Lurasidone was previously…
read more here.
Keywords:
thrombocytopenia signal;
myelosuppression;
drug;
induced thrombocytopenia ... See more keywords